Abstracts tagged "osteoporosis"

Abstract Number: 1442 • ACR Convergence 2020
Denosumab versus Oral Bisphosphonate for Osteoporosis in Long-term Glucocorticoid Users: A 12-month Randomized Controlled Trial
Chi Chiu Mok¹, Ling Yin Ho¹ and Kwok Man Ma¹, ¹Tuen Mun Hospital, Hong Kong, China (People's Republic)
Background/Purpose: To compare the efficacy of denosumab (DEN) and oral alendronate (ALN) on spinal bone mineral density (BMD) in long-term glucocorticoid users.Methods: Patients receiving long-term…
Abstract Number: 0109 • ACR Convergence 2020
Glucocorticoid-Induced Osteoporosis: Are We Practicing Prevention?
Eileen Rife¹, Emejuaiwe Nkechinyere² and Jose Leon de la Rocha³, ¹Louisiana State University, Metairie, LA, ²Department of Veterans Affairs, New Orleans, LA, ³Louisiana State University, Auburn, AL
Background/Purpose: Descriptive study designed to assess compliance to evidence-based practice guidelines for the prevention of Glucocorticoid-Induced Osteoporosis (GIOP).Methods: We queried the electronic database of the…
Abstract Number: 0129 • ACR Convergence 2020
Glucocorticoid-Induced Osteoporosis in Patients with Chronic Inflammatory Rheumatic Diseases: A Multivariate Linear Regression Analysis Identifying Factors Affecting Bone Mineral Density
Edgar Wiebe¹, Desiree Freier¹, Dörte Huscher², Sandra Hermann¹, Robert Biesen³ and Frank Buttgereit⁴, ¹Charité University Medicine Berlin, Dep. of Rheumatology and Clinical Immunology, Berlin, Germany, ²Charité University Medicine Berlin, Dep. of Biometry and Clinical Epidemiology, Berlin, Germany, ³Charité University Medicine, Dep. of Rheumatology and Clinical Immunology, Berlin, ⁴Charité University Medicine, Berlin, Germany
Background/Purpose: Rheumatic diseases are associated with increased systemic bone loss and fracture risk related to chronic inflammation, disease-specific, general and demographic risk factors as well…
Abstract Number: 1558 • ACR Convergence 2020
Cinematic Rendering Enables Depiction of Bone Anabolic Effects in Patients Treated with Baricitinib
Sara Bayat¹, David Simon², Louis Schuster², Georg Schett³ and Arnd Kleyer², ¹Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ²Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, ³Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany
Background/Purpose: Preclinical studies show that tsDMARDs such as baricitinib may be a therapeutic agent for bone anabolic effects by increasing osteoblast function in inflammatory conditions.[1]…
Abstract Number: 0111 • ACR Convergence 2020
Assessment and Treatment of Glucocorticoid-Induced Osteoporosis in a Rheumatology Clinic
Amanda Stefl¹, Shikha Singla², Jessica Michaud¹, Kama Thomas², Lisa Rein² and Mary Ellen Csuka², ¹Froedtert Hospital, Milwaukee, WI, ²Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Glucocorticoids (GC) are used as a long-term treatment option for an estimated 1% of the US population. The American College of Rheumatology has maintained…
Abstract Number: 0130 • ACR Convergence 2020
The Prevalence of Osteoporosis in Individuals with Osteoarthritis: A Systematic Review
Timothy Varghese¹, Ali Ahmadi Pirshahid², Dongkeun Kim² and Yueyang Li², ¹Schulich School of Medicine & Dentistry, Richmond Hill, ON, Canada, ²Schulich School of Medicine & Dentistry, London, ON, Canada
Background/Purpose: There is controversy regarding the relationship between osteoarthritis (OA) and osteoporosis (OP). While OA may be associated with increased bone mineral density (BMD) due…
Abstract Number: 1588 • ACR Convergence 2020
A Quality Improvement Project to Improve Bone Densitometry Ordering in Adult Patients on Chronic Glucocorticoids
Katherine Kaufman¹, Philip Chu¹, Mithu Maheswaranathan¹, Andrew Johannemann¹, D Ryan Anderson¹, Isaac Smith¹, Akrithi Udupa¹, Mary Buckley¹, Laura Cannon¹, Rachel Randell¹ and David Leverenz¹, ¹Duke University, DURHAM, NC
Background/Purpose: The 2017 ACR guideline for glucocorticoid-induced osteoporosis (GIOP) recommends DXA testing in patients aged ≥40 years on chronic glucocorticoids. We performed a quality improvement…
Abstract Number: 0112 • ACR Convergence 2020
Description of Risk Factors at Baseline and Need of Bone Agent According to Hadji Recommendations in Patients Taking Aromatase Inhibitors as Breast Cancer Therapy
David Montero-Seisdedos¹, Oihane Ibarguengoitia-Barrena², Lucía Vega-Álvarez², Carmen Lucía García Gomez², Itziar Calvo-Zorrilla³, Juan M. Blanco-Madrigal², Maria Esther Ruiz-Lucea², María Luz García-Vivar², Eva Galindez-Agirregoikoa², Ana R. Inchaurbe-Pellejero², Olaia Fernandez-Berrizbeitia², Clara E. Perez-Velasquez², Eduardo Cuende-Quintana⁴, Amaia Bilbao-González³ and Iñaki Torre-Salaberri³, ¹Basurto University Hospital, Bilbao, Pais Vasco, Spain, ²Basurto University Hospital, Bilbao, Spain, ³University Hospital of Basurto, Bilbao, Pais Vasco, Spain, ⁴Basurto University Hospital, Madrid, Spain
Background/Purpose: A well-known adverse effect of aromatase inhibitors (AI) in the bone is the loss of mineral density with the consequent increased risk of fracture…
Abstract Number: 0131 • ACR Convergence 2020
Analysis of the Total Body Composition in a Cohort of Patients with Elderly Onset Arthritis
Anahy María Brandy García¹, Melania Martinez-Morillo², Agueda Prior³, Rosa Serrano¹, Lourdes Mateo⁴, Monica Guma⁵ and Laia Gifre², ¹Hospital Germans Trias i Pujol, Badalona, Spain, ²Hospital Germans Trias i Pujol, Barcelona, Spain, ³Department of Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, ⁴Department of Rheumatology, Germans Trias i Pujol. University Hospital, Badalona, Badalona, ⁵University of California San Diego, La Jolla, CA
Background/Purpose: Inflammatory arthritis in the elderly leads to greater comorbidity than that of the young patients, however, there are few data on body composition in…
Abstract Number: 1590 • ACR Convergence 2020
Bone Health in ANCA – Associated Vasculitis Patients
Deepa Ragesh Panikkath¹, Sandy Lee² and Christina Downey², ¹Loma Linda University Health, Department of Rheumatology, Loma Linda, CA, ²Loma Linda University Medical Center, Redlands, CA
Background/Purpose: Glucocorticoids (GC) are an important mode of therapy in ANCA associated vasculitis (AAV), and osteoporosis (OP) and fractures are potential adverse effects seen. The…
Abstract Number: 0113 • ACR Convergence 2020
Improving Glucocorticoid-Induced Osteoporosis Screening and Management in Patients with Rheumatic Diseases Using the 2017 ACR Guidelines
Marielys Figueroa Sierra¹, Atefeh Vafa¹, Shu Cao², Yuanyuan Lu³, Helen Bateman⁴, John Carter¹, Yih Chang Lin², Raquel Cuchacovich¹, Marcos Maldonado⁴, Joanne Valeriano-Marcet¹ and Gabriela Montes-Rivera⁴, ¹University of South Florida, Tampa, FL, ²University of South Florida, Morsani College of Medicine, Tampa, FL, ³Biostatistician at Graduate Medical Education Department, Tampa, FL, ⁴James A. Haley VA, Tampa, FL
Background/Purpose: Glucocorticoid-induced osteoporosis (GIOP) is a potentially preventable complication in those who are maintained on glucocorticoid (GC) therapy. It is imperative to identify these patients…
Abstract Number: 0132 • ACR Convergence 2020
Prevalence of Osteoporosis and Fragitlity Fractures Is Not Different Between ACPA Positive Patients Compared to ACPA Negative Patients in a Real World Setting, Despite Longer Disease Duration and Glucocorticoid-Treatment
Edgar Wiebe¹, Desiree Freier¹, Dörte Huscher², Gloria Dallagiacoma³, Sandra Hermann¹, Robert Biesen⁴, Gerd Burmester⁵ and Frank Buttgereit⁶, ¹Charité University Medicine Berlin, Dep. of Rheumatology and Clinical Immunology, Berlin, Germany, ²Charité University Medicine Berlin, Dep. of Biometry and Clinical Epidemiology, Berlin, Germany, ³University of Verona, Dep. of Rheumatology, Verona, Italy, ⁴Charité University Medicine, Dep. of Rheumatology and Clinical Immunology, Berlin, ⁵Charité University Hospital Berlin, Berlin, Germany, ⁶Charité University Medicine, Berlin, Germany
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased systemic bone loss, leading to a high risk for hip, vertebral and non-hip, non-vertebral fractures. Especially ACPA…
Abstract Number: 1591 • ACR Convergence 2020
A Quality Improvement Project to Increase Vitamin D Prescribing for Pediatric Patients on Glucocorticoids
Katherine Kaufman¹, Mary Buckley¹, Laura Cannon¹, Rachel Randell¹, Philip Chu¹, Mithu Maheswaranathan¹, Andrew Johannemann¹, D Ryan Anderson¹, Isaac Smith¹, Akrithi Udupa¹ and David Leverenz¹, ¹Duke University, DURHAM, NC
Background/Purpose: Chronic glucocorticoid treatment in children increases the risk of bone loss, fractures, and reduced adult skeletal mass. The 2017 ACR Glucocorticoid-Induced Osteoporosis (GIOP) guidelines…
Abstract Number: 0114 • ACR Convergence 2020
Incidence of Follow-Up Dual-Energy X-Ray Absorptiometry Scanner Error: A Contributor to Precision Error
Kevin Lee¹, Karam Al Jumaily¹, Mu Lin², Kerry Siminoski³ and Carrie Ye⁴, ¹Internal Medicine, University of Alberta, Edmonton, AB, Canada, ²Alberta Health Services, Edmonton, AB, Canada, ³Radiology, University of Alberta, Edmonton, AB, Canada, ⁴Rheumatology, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Osteoporosis is characterized by decreased bone tissue microarchitecture. This leads to reduced bone density and quality and is a significant contributor to morbidity, mortality,…
Abstract Number: 0133 • ACR Convergence 2020
Pharmacist-Driven Clinic Development for Patients with Incidental Vertebral or Hip Fractures
Julie Ferm¹, Lanh Dang¹ and Gurjit Kaeley², ¹UF Health Jacksonville, Jacksonville, FL, ²University of Florida College of Medicine - Jacksonville, Jacksonville, FL
Background/Purpose: Non-traumatic vertebral and hip fractures are detrimental complications of osteoporosis and those with a previous fracture have double the risk of subsequent fractures. The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].